A Phase II study to evaluate the safety and potential palliative benefit of intraperitoneal bevacizumab in patients with symptomatic ascites due to advanced chemotherapy resistant gynaecological cancers: REZOLVE dataset

This dataset includes 24 female participants (38 86 years old) receiving intraperitoneal bevacizumab recruited into the REZOLVE study from six hospitals in New South Wales, Queensland and Victoria, Australia. Baseline data includes demographics, ECOG performance status, prior systemic treatment, doses of the intervention administered, clinical chemistry, quality of life, adverse events and overall survival. Follow-up data was collected within three months after the first intraperitoneal administration of bevacizumab and includes adverse events and quality of life. The file type is .XLS.